Are Peptides Legal in Canada? BPC-157 and the Regulatory Rules

Peptides have moved from bodybuilding forums into mainstream wellness marketing. Products like BPC-157, TB-500 and ipamorelin now appear in online stores, medical spas and gyms across Canada, sold for injury recovery, anti-aging and performance. The marketing is confident. The regulatory reality is not. In Canada, most of these peptides are unapproved prescription drugs, and selling them the way they are commonly sold is illegal.

This gap between how peptides are marketed and how Health Canada classifies them creates real legal and financial exposure for clinics, importers, distributors and supplement brands. On April 9, 2026, Health Canada issued a public advisory warning consumers about unauthorized injectable peptide drugs, naming BPC-157 among the products it has seized. This article explains how Canada classifies peptides, why BPC-157 and similar compounds are not lawful to sell, how the United States picture differs, and what a compliant pathway actually looks like.

What are peptides, and how does Canada classify them?

Direct answer: peptides are short chains of amino acids that behave like drugs when they change how the body works, so Health Canada regulates most therapeutic peptides as drugs under the Food and Drugs Act and the Food and Drug Regulations. The classification depends on the ingredient, the claims and the route of administration, not on what the seller calls the product.

A product is a drug in Canada if it is represented for use in the diagnosis, treatment, mitigation or prevention of a disease, or to restore, correct or modify organic functions in humans. Peptides such as BPC-157 and TB-500 are promoted precisely on that basis, to heal tissue, reduce inflammation or alter metabolism, so they meet the drug definition by design. Once a product is a drug, it cannot lawfully be sold in Canada unless Health Canada has authorized it and issued a Drug Identification Number (DIN) or a Notice of Compliance.

The table below shows how different peptide products map onto the Canadian framework.

Many sellers hope to route peptides through the natural health product framework. That door is closed. Natural health products are intended for self-care and are taken orally or applied topically. A product administered by injection is excluded from the NHP category and is regulated as a drug. So even where a peptide might sound natural, the injectable route alone removes it from the supplement market.

Why BPC-157 and similar peptides are not legal to sell in Canada

Direct answer: BPC-157 and comparable peptides have never been assessed or authorized by Health Canada, so they have no DIN and no market authorization. Under the Food and Drugs Act, an unauthorized drug cannot lawfully be sold, imported or advertised in Canada, and Health Canada has been actively seizing these products and working with the Canada Border Services Agency to stop shipments at the border.

In its April 2026 advisory, Health Canada listed examples of unauthorized injectable peptide drugs it had seized, including BPC-157, CJC-1295, DSIP, Epitalon, GHK-Cu, HCG, ipamorelin, KPV, Melanotan I and II, MOTS-c, NAD+, SS-31, TB-500 and retatrutide. It stressed that many other unauthorized peptides exist and should all be avoided. The agency warned that these products have not been assessed for safety, efficacy or quality, and that users risk hormonal imbalance, blood clots, liver or kidney damage, contamination and incorrect dosing.

There is a simple test any buyer or seller can run. Authorized drugs in Canada carry an eight-digit DIN on the label, and you can confirm a product using Health Canada's Drug Product Database. If a peptide product has no DIN, it has not been authorized, and it cannot be sold legally, regardless of how it is described online.

How the United States picture differs, and why it does not help Canadian sellers

Direct answer: the United States is debating whether pharmacies may compound certain peptides, but that is a compounding question, not an approval, and it has no effect on Canadian law. A Canadian business cannot rely on US developments to sell peptides here.

On July 23 and 24, 2026, the US Food and Drug Administration's Pharmacy Compounding Advisory Committee reviewed BPC-157, KPV, TB-500, MOTS-c and other peptides for possible inclusion on the section 503A bulk drug substances list, which governs what US compounding pharmacies may prepare. The committee's recommendations are non-binding, and the FDA makes the final decision. Even a favourable compounding outcome is not the same as marketing approval, and it applies only to US pharmacies operating under US federal and state rules.

For a Canadian clinic, importer or brand, none of this changes anything. Importing peptides from foreign research suppliers for human use remains illegal in Canada, and Health Canada is coordinating with the Canada Border Services Agency to intercept these shipments. Watching US headlines and assuming the rules have loosened here is one of the fastest ways to end up holding seized inventory.

What a compliant peptide pathway looks like in Canada

Direct answer: a lawful peptide product needs the correct classification, an authorized drug submission that earns a DIN or Notice of Compliance, and, for anyone fabricating, importing, packaging, labelling, testing or distributing it, a Drug Establishment Licence. For most of the BPC-157 style peptides, no such authorization exists or is being pursued, so there is no lawful commercial route today.

The honest message for most peptide sellers is uncomfortable but clear. If your product is one of the unapproved peptides, the compliant action is to stop selling, remove the health claims and dosing guidance, and seek advice on whether any legitimate pharmaceutical pathway is realistic. For a genuine drug developer with data, the pathway exists, but it runs through a full drug submission, not a supplement label.

Which peptides are affected, and what they are sold for

Direct answer: Health Canada's April 2026 advisory named more than a dozen peptides it had seized, and the list is not exhaustive. The products are marketed for recovery, anti-aging, weight loss, tanning and general wellness, but every one of them is an unauthorized drug in Canada. The marketing claim does not change the status.

The table below summarizes the peptides named in the advisory and the claims commonly attached to them. It is a snapshot to help you recognize the category, not a shopping list. None of these products has a Drug Identification Number, and none can be sold legally.

Health Canada was explicit that many other unauthorized peptides exist and should all be avoided. So a peptide that does not appear on this list is not therefore permitted. The default position for any therapeutic peptide with no DIN is that it cannot be sold, imported or advertised in Canada.

Enforcement is active, not theoretical

Direct answer: Health Canada has moved from warnings to seizures. It has issued multiple advisories over 2025 and 2026 about unauthorized injectable peptides taken from clinics, wellness centres and retail stores, and it is coordinating with the Canada Border Services Agency to intercept shipments at the border. This is enforcement in progress, not a distant risk.

For a business, the exposure is practical and financial. Seized inventory is money gone. A stop-sale order can halt a product line overnight. Advertising an unauthorized drug is itself an offence under the Food and Drugs Act, so the marketing that drives sales is also part of the liability. For a clinic that injects patients, there is added risk: administering a product that has not been assessed for identity, purity or sterility can cause real harm, and the clinic, not the overseas supplier, is the party a regulator and an injured patient will pursue.

The safest course is to treat every peptide product as a drug until proven otherwise, confirm the DIN before you touch it, and get a classification opinion in writing. A short review at the start is far cheaper than a seizure, a recall or an enforcement letter later.

The bottom line for each type of business

Direct answer: the right response depends on your role, but for most businesses handling the popular peptides today, the compliant action is to stop and reassess before continuing. The framework below shows how the rules land on the three groups most often involved.

Clinics and practitioners. A professional licence lets you treat patients, but it does not authorize you to source, sell or inject an unapproved drug. If a peptide has no DIN, administering it puts the clinic at the front of any enforcement or liability action. Review your inventory, remove unauthorized products, and use only authorized drugs obtained through a licensed pharmacy.

Importers and distributors. Bringing an unauthorized peptide into Canada, even as a bulk ingredient or a research chemical, is an import of an unauthorized drug. The Canada Border Services Agency and Health Canada are actively intercepting these shipments. Confirm authorization and your Drug Establishment Licence coverage before you place an order, not after the goods are detained.

Supplement and wellness brands. A peptide cannot be repositioned as a supplement to avoid the drug rules. If your product line includes injectable or therapeutic peptides, it belongs in the drug framework, and the honest options are to pursue proper authorization or to discontinue the product. A written classification opinion tells you which, before a regulator does.

Compliance checklist for peptides in Canada

• Confirm classification before you buy, sell, import or advertise any peptide product.
• Check the Drug Product Database for a valid DIN. No DIN means no lawful sale.
• Do not rely on Research Use Only labelling to sell products for human use.
• Treat every injectable peptide as a drug, never as a natural health product or supplement.
• Do not import peptides from foreign research suppliers for human use.
• If you handle authorized drugs, verify that your Drug Establishment Licence covers the activity.
• Remove health claims, benefit statements and dosing guidance for any unauthorized product immediately.

Common mistakes we see

• Selling peptides as supplements or nutraceuticals. They meet the drug definition and injectables cannot be natural health products.
• Assuming a US compounding decision legalizes sale in Canada. It does not. Canadian law is separate and these peptides remain unauthorized here.
• Relying on Research Use Only disclaimers. Health Canada rejects this framing outright.
• Believing a clinic or practitioner licence authorizes it. A professional licence does not authorize the sale or administration of an unapproved injectable drug.
• Importing bulk peptide powder as an ingredient. An unauthorized active pharmaceutical ingredient is still unauthorized.
• Advertising benefits online. Advertising an unauthorized drug is itself an offence under the Food and Drugs Act.

Frequently asked questions

Is BPC-157 legal to buy or sell in Canada?

No. BPC-157 has no Drug Identification Number and no market authorization in Canada. Selling, importing or advertising it is illegal, and Health Canada has seized it and is working with the Canada Border Services Agency to stop shipments.

Are peptides considered natural health products in Canada?

Generally no. Therapeutic peptides act as drugs, and injectable products are excluded from the natural health product framework, so they are regulated as drugs under the Food and Drugs Act and the Food and Drug Regulations.

Does a Research Use Only label make peptides legal?

No. Health Canada has stated that this labelling does not make a product legal or exempt it from regulatory requirements. If the product is intended for or realistically destined for human use, it is treated as an unauthorized drug.

Can a clinic or naturopath legally administer BPC-157?

Not if the product is unauthorized. A professional licence does not authorize the sale or administration of an unapproved drug. Administering a seized, unauthorized injectable also exposes the practitioner and the clinic to enforcement and liability risk.

What is the difference between the US and Canadian approach?

The United States is debating whether pharmacies may compound certain peptides, which is a compounding question. Canada regulates these peptides as unapproved prescription drugs. A US compounding decision does not change Canadian law or make sale here lawful.

How can a company sell a peptide product legally in Canada?

By obtaining market authorization, a DIN or Notice of Compliance, through the appropriate drug submission, and by holding the Drug Establishment Licence and Good Manufacturing Practices systems required for the activities it performs. There is no supplement or research shortcut.

How MFLRC can help

MFLRC helps companies navigate exactly this kind of classification uncertainty. If you sell, import or are considering a peptide product, our Regulatory Affairs, Licensing and Import and Export team can determine how Health Canada will classify it, map the regulatory pathway, and tell you honestly whether a lawful route exists before you commit money or inventory.

We support DIN and drug submission strategy, Drug Establishment Licence applications, import and export compliance, and quality assurance and GMP readiness, including gap assessments, SOP development and audit preparation. Where a product cannot be made compliant, we say so early, so you can change course before an inspector or the Canada Border Services Agency does it for you.

If you are unsure how a peptide or any borderline product will be classified in Canada, talk to us before you list it, import it or advertise it.

Conclusion

Peptides are not a regulatory grey area in Canada. Most therapeutic peptides are drugs, most of the popular ones are unauthorized, and selling or importing them is illegal. The confident marketing around BPC-157 and its relatives does not change the classification, and neither does a US compounding debate or a Research Use Only sticker. The businesses that get hurt are the ones that treat a drug like a supplement. If authorized drugs are part of your operation, the same discipline that keeps you inspection ready will keep you clear of unauthorized products. Classify first, verify the DIN, and get advice before you act.

Sources and references

• Health Canada. Think twice before injecting peptides bought online (public advisory RA-81874, April 9, 2026).
• Health Canada. Drug Product Database.
• Government of Canada. Food and Drugs Act (RSC, 1985, c. F-27).
• Government of Canada. Natural Health Products Regulations (SOR/2003-196).
• US FDA. July 23 to 24, 2026 Meeting of the Pharmacy Compounding Advisory Committee.